Startseite>>Signaling Pathways>> Ubiquitination/ Proteasome>> Autophagy>>Ranolazine 2HCl

Ranolazine 2HCl (Synonyms: RS 43285)

Katalog-Nr.GC13882

Ranolazin 2HCl (CVT 303 Dihydrochlorid) ist ein Anti-Angina-Medikament, das seine Wirkung erzielt, indem es die spÄte Phase des nach innen gerichteten Natriumstroms (INa und IKr mit IC50-Werten von 6 μM bzw. 12 μM) hemmt, ohne die Herzfrequenz zu beeinflussen oder Blutdruck (BP).

Products are for research use only. Not for human use. We do not sell to patients.

Ranolazine 2HCl Chemische Struktur

Cas No.: 95635-56-6

Größe Preis Lagerbestand Menge
10mM (in 1mL DMSO)
42,00 $
Auf Lager
10mg
38,00 $
Auf Lager
200mg
107,00 $
Auf Lager

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Ranolazine dihydrochloride (CVT 303 dihydrochloride) is an anti-angina drug that achieves its effects by inhibiting the late phase of inward sodium current (INa and IKr with IC50 values of 6 μM and 12 μM, respectively) without affecting heart rate or blood pressure (BP)[1][2]. Ranolazine dihydrochloride is also a partial fatty acid oxidation inhibitor[3].

Ranolazine (Bolus injection 10 mg/kg and infusion 9.6 mg/kg/h; bolus injection; for 145 minutes; male Wistar rats) treatment significantly reduces infarct size and cardiac troponin T release in rats subjected to left anterior descending coronary artery occlusion-reperfusion[3].

References:
[1]. Keating GM. Ranolazine: A Review of Its Use as Add-On Therapy in Patients with Chronic Stable Angina Pectoris. Drugs. 2013 Jan;73(1):55-73.
[2]. Wang WQ, Robertson C, Dhalla AK, Belardinelli L. Antitorsadogenic effects of ({+/-})-N-(2,6-dimethyl-phenyl)-(4[2-hydroxy-3-(2-methoxyphenoxy)propyl]-1-piperazine (ranolazine) in anesthetized rabbits. J Pharmacol Exp Ther. 2008 Jun;325(3):875-81. doi: 10.1124/jpet.108.137729. Epub 2008 Mar 5.
[3]. Zacharowski K, Blackburn B, Thiemermann C. Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur J Pharmacol. 2001 Apr 20;418(1-2):105-10.

Bewertungen

Review for Ranolazine 2HCl

Average Rating: 5 ★★★★★ (Based on Reviews and 6 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Ranolazine 2HCl

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.